SARS-COV-2 vaccine responses in renal patient populations

BMC Nephrology

Table 2 Detailed characteristics of the transplant group

	N = 209
Time since most recent transplant (days) (median (IQR))	1264 (355–3788)
Cause of ESKD (Number (%))
- Diabetic nephropathy	46 (22)
- Renovascular disease	7 (3)
- Glomerulonephritis	47 (23)
- Unknown	30 (14)
- Other	79 (38)
Type of transplant (Number (%))
- Kidney	178 (85)
- Simultaneous kidney pancreas	29 (14)
- Other	3 (1)
Previous failed transplant (Number (%))	25 (12)
GFR (ml/min/m²) (median (IQR))	49 (34–90)
Concurrent immunosuppression^a (Number (%))
- 3 agents	68 (33)
- 2 agents	109 (52)
- 1 agent	31 (15)
Mycophenolate mofetil (Number (%))^b	130 (62)
- Daily dose (mg) (median (IQR))	1000 (500–1000)
Prednisolone (Number (%))	118 (56)
- Total daily dose (mg) (median (IQR))	3 (0–5)
Tacrolimus (Number (%))	205 (98)

All transplant patients were recruited from Cambridge. Data are reported at the time of most recent sampling. Basiliximab induction was used for low/medium risk kidney transplant recipients, alemtuzumab induction was used for high risk kidney and simultaneous pancreas kidney transplant recipients. ^aConcurrent immunosuppression includes glucocorticoids. ^bMycophenolate mofetil (MMF) number includes all patients receiving any mycophenolic acid (MPA) preparation; doses were converted to the equivalent MMF doses for the purpose of understanding relative MPA dosing. Fourteen patients had prior rituximab exposure; 10 within the last 5 years; 5 for post transplant lymphproliferative disorder and 4 for autoimmune disease. Thirty-four received alemtuzumab induction

ISSN: 1471-2369